Published Papers

Below is a listing of selected recently published papers by Dr. Gregory T. Everson, and in collaboration with industry peers:

Authors’ Response to “Editorial: stratifying risk of adverse outcomes in cirrhosis: the
Hepquant SHUNT test”. Asrani S, Everson GT. Alimentary Pharmacology and
Therapeutics. 2021.

Editorial: Stratifying risk of adverse outcomes in cirrhosis: the Hepquant SHUNT
test. Maan R, Sonneveld MJ Alimentary Pharmacology and Therapeutics. 2021. In pressliver function publications

Feb. 8, 2021 — Predicting clinical decompensation in patients with cirrhosis using the Hepquant‐SHUNT test | Mohammad Amin Fallahzadeh Daniel J. Hansen James F. Trotter Gregory T. Everson Giovanna Saracino Robert S. Rahimi Steve Helmke Jodi Boutte Sumeet K. Asrani | Alimentary Pharmacology and Therapeutics

Jan. 2, 2021 —  The within-individual reproducibility of the disease severity index from the HepQuant SHUNT test of liver function and physiology. Burton JR Jr, Helmke S, Lauriski S, Kittelson J, Everson GT. | Transl Res. 2021 Jan 2;S1931-5244(20)30321-2. doi: 10.1016/j.trsl.2020.12.010.

Nov. 2020 — Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation | Verna EC, Serper M, Chu J, Corey K, Fix OK, Hoyt K, Page KA, Loomba R, Li M, Everson GT, Fried MW, Garcia-Tsao G, Terrault N, Lok AS, Chung RT, Reddy KR. | Hepatology 2020 Nov;72(5):1819-1837. doi: 10.1002/hep.31491.

Aug. 4, 2020 — Deterioration in Liver Function after Liver-Directed Therapy for Hepatocellular Carcinoma Measured by Cholate Clearance (University of Pennsylvania) | Division of Gastroenterology and Hepatology | Accepted Aug. 4, 2020

Jul. 16, 2019 — Assessing Hepatic Impairment in Fontan‐Associated Liver Disease Using the HepQuant SHUNT Test  |Division of Gastroenterology & Hepatology, Department of Medicine, Northwestern University Feinberg School of Medicine | Accepted July 16, 2019 | Congenit Heart Dis. 2019 Aug 1. doi: 10.1111/chd.12831.

Go To Publication Archives